Cash and Cash Equivalents: As of September 30, 2025, Kymera had $978.7 million in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash ...

Q3 2025 Earnings Call Transcript November 3, 2025 Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS ...

All this screen time isn’t just negatively affecting our sleep, but also taking a toll on our skin quality by increasing our ...

For decades, tax reform in Nigeria has carried a heavy undertone — the expectation that government policy would mean higher ...

Q3 2025 Earnings Call Transcript October 30, 2025 Phathom Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million ---- December 20, 2025 PDUFA goal date ...

Viking Therapeutics, Inc. progressing rapidly with its Phase 3 VANQUISH trials of VK2735 set to complete enrolment. Learn ...

Hearing from fourth year students does help to calm my nerves. Despite learning of some quite chaotic experiences ...

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability ...

Stacker compiled a list of the best counties to live in New York.

Doctors, nurses, and ASHAs face rising assaults amid staff shortages and state inaction. India’s healthcare crisis reveals ...